BioSpace News Archive

As state and local governments across the United States begin to lift mitigation efforts, the death toll continues to climb across the globe, a reminder that COVID-19 is still a serious public health concern.

Andrey Tolmachov issued a letter to the global drug discovery and scientific community, underscoring the importance of condemnation and action against Russian invasion.

Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced the launch of the Clareon® family of intraocular lenses in the U.S. Utilizing Alcon’s most advanced IOL material, Clareon can deliver consistent visual outcomes and exceptional clarity that lasts.

The SanBio Group hereby announces the completion of an application filing with Japan’s Ministry of Health, Labour, and Welfare for manufacture and marketing approval as a regenerative medicine product for the investigational product SB623, as a treatment for chronic motor deficit from traumatic brain injury.

Oxurion NV announces that it successfully completed a private equity placement by which it raised EUR 10.4 million in gross proceeds for 7,226,039 new shares issued at EUR 1.44.

PathMaker Neurosystems Inc. announced initiation of its U.S. multi-center clinical trial to evaluate MyoRegulator® for the non-invasive treatment of post-stroke upper-limb spasticity.

Evelo Biosciences, Inc. announced that it will host a virtual event titled, “The Future: A no regrets treatment for all stages of psoriasis and broader inflammatory disease.” The event will be held virtually on Friday, March 11, 2022, beginning at 8:00 a.m. ET.

Kinnate Biopharma Inc. announced the presentation of findings from a collaborative study with Tempus investigating the prevalence of Class II and Class III alterations among patients with BRAF-mutated solid tumors.

Acer Therapeutics Inc. (Nasdaq: ACER), today announced that it has entered into convertible note and loan financing facilities for up to $48.5 million with affiliates of Marathon Asset Management L.P. (Marathon) and SWK Holdings Corporation (Nasdaq: SWKH), subject to certain conditions.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the initiation of the Phase 3 KONFIDENT clinical trial evaluating the efficacy and safety of KVD900 as the first potential oral, on-demand therapy for hereditary angioedema (HAE) attacks.